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Background
Berardinelli-Seip congenital Lipodystrophy (BSCL) is a
rare autosomal recessive disease characterized by almost
complete absence of adipose tissue. Because of it, they
have hypertriglyceridemia with fat ectopic deposits and
regularly develop diabetes mellitus and steatohepatitis.
Objectives
Primary objective: Evaluate the grade of steatosis and
liver fibrosis, the body composition and metabolic pro-
file of three patients with BSCL. Second: evaluate the
body composition in this syndrome with Dual energy
X-ray absortiometry (DEXA).
Method
Hepatic impairment was evaluated by liver elastography
ultrasound through wave M and X using FibroScan 502.
DEXA (Lunar Prodigy Advance) and also Bioimpedance
analysis (InBody 270) were used to assess body composi-
tion. Blood samples were collected after 12 hour fasting
state to measure lipids and glycemia. There retina were
also by indirect ophthalmoscopy method.
Results
Patients 1 and 3 were diagnosed late, by the age of 54
and 43 yrs. respectively. While the second patient was
diagnosed earlier at 17th and follows 14 yrs. in treatment.
All patients have low body fat on DEXA (Figure 1) and
moderate steatosis, but only the Patient 2 has no fibrosis.
The patients’ metabolic profile after the treatment is
exposed at Table 1. All patients are in use, at least for
2 yrs., of TZD (30 mg/day), MTF (2000mg/day), insulin
(2.01 UI/kg±0.36) and atorvastatin (20-40 mg/day ). Only
Patients 2 and 3 are in use fibrate because the Patient 1
had CPK elevation with this. Patient 2 fundoscopy
showed significant deposition of triglycerides in her
retina (Figure 2).
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Figure 1 Patient lean body mass and body fat
Table 1 The patients' metabolic profile after the
treatment
PATIENT 1 PATIENT 2 PATIENT 3
Weight (kg) 59 65.8 54.5
TGL (mg/dL) 597 151 510
HDL (mg/dL) 19 32 45
Fasting plasma glucose (mg/dL) 121 67 200
HbA1c% 8,5 5,9 10
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Conclusion
Steatosis duration seems to be an important factor for
liver fibrosis, since the two oldest patients had fibrosis
and the youngest did not. These patients have very low
percentage of fat tissue by DEXA. Hyperglycemia and
hypertriglyceridemia in BSCL patients is very common,
despite the use of insulin sensitizers, high doses of insulin
and lipid-lowering agents.
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Figure 2 Patient 2 fundoscopy.
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